Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Alimera Sciences Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ALIM
Nasdaq
2834
https://alimerasciences.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Alimera Sciences Inc
Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences
- May 7th, 2024 12:00 pm
Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update
- Apr 30th, 2024 12:00 pm
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mar 20th, 2024 12:00 pm
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
- Mar 19th, 2024 12:00 pm
Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call Transcript
- Mar 8th, 2024 3:05 pm
Q4 2023 Alimera Sciences Inc Earnings Call
- Mar 8th, 2024 4:18 am
Alimera Sciences Inc (ALIM) Reports Significant Revenue Growth in Q4 and Full Year 2023
- Mar 7th, 2024 6:55 pm
Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates
- Mar 7th, 2024 2:00 pm
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
- Mar 7th, 2024 12:30 pm
Alimera Sciences, Inc. (NASDAQ:ALIM) Has Found A Path To Profitability
- Mar 6th, 2024 10:55 am
Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update
- Feb 29th, 2024 1:00 pm
The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®
- Feb 8th, 2024 1:00 pm
Alimera Sciences (NASDAQ:ALIM) shareholders have endured a 69% loss from investing in the stock five years ago
- Jan 25th, 2024 12:24 pm
Alimera Completes Recruitment for the Synchronicity Study
- Jan 4th, 2024 1:00 pm
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Jan 2nd, 2024 1:00 pm
Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Dec 12th, 2023 12:30 pm
Alimera Appoints Maggie A. Pax to Its Board of Directors
- Nov 8th, 2023 9:30 pm
Alimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of Ophthalmology
- Oct 31st, 2023 12:00 pm
Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2023 Earnings Call Transcript
- Oct 27th, 2023 1:26 pm
Alimera Sciences Inc (ALIM) Reports Q3 2023 Financial Results
- Oct 26th, 2023 1:29 pm
Scroll